首页> 外文OA文献 >Factor VIII inhibitors development following introduction of B-domain-deleted recombinant factor VIII in four hemophilia A previously treated patients

【2h】

Factor VIII inhibitors development following introduction of B-domain-deleted recombinant factor VIII in four hemophilia A previously treated patients

机译：在四个血友病中引入B-域缺失的重组因子VIII后，因子VIII抑制剂显影在四种血友病中预先治疗的患者

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
V. Roussel-Robert; M. F. Torchet; F. Legrand; C. Rothschild; N. Stieltjes;
展开▼
作者单位

展开▼
年度 2003
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Rates of inhibitor development in previously untreated patients with severe hemophilia a treated with plasma-derived or recombinant factor VIII: No proof of difference or proof of no difference? [J] . MessoriA., FaddaV., MarateaD., Seminars in Thrombosis and Hemostasis . 2014,第2期

机译：在先前未经治疗的严重血友病患者中用血浆来源的或重组的凝血因子VIII治疗的抑制剂发生率：无差异证据或无差异证据？
2. Response to rates of inhibitor development in previously untreated patients with severe hemophilia a treated with plasma-derived or recombinant factor VIII: No proof of difference or proof of no difference? [J] . FranchiniM., MengoliC. Seminars in Thrombosis and Hemostasis . 2014,第2期

机译：对先前未经治疗的严重血友病患者中血浆衍生或重组凝血因子VIII对抑制剂形成速率的反应：无差异证据或无差异证据？
3. Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: A systematic review [J] . IorioA., HalimehS., HolzhauerS., Journal of thrombosis and haemostasis: JTH . 2010,第6期

机译：先前未经治疗的血友病中抑制剂发展的速度用血浆来源或重组凝血因子VIII浓缩物治疗的患者：系统评价
4. Inactiwatlon of Animal Factor VIII by human Factor VIII Inhibitors: Inwestigation of Plasma from Patients with Inhibitors in congenital Hemophilia I and from Patients with acquired Hemophilia A [C] . V. Aumann, G. Lutze (Jr.), G. Lutze (Sen.), Hemophilie-Symposion . 2003

机译：人为因子VIII抑制剂的动物因子VIII的乙酰丁酮：先天性血友病药中抑制剂患者的血浆中的预防
5. Satisfaction, Adherence, and Recombinant Factor VIII Choice of Patients with Moderate to Severe Hemophilia A [D] . Strickland, Kimberly. 2020

机译：满意度，依从性和重组因素VIII患者中度至重度血友病的患者
6. Phase I study of BAY 94-9027 a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life in subjects with hemophilia A [O] . T E Coyle, M T Reding, J C Lin, -1

机译：BAY 94-9027 I期研究在患有血友病A的受试者中进行这是一种具有半衰期延长的PEG化B结构域缺失的重组因子VIII
7. Rates of Inhibitor Development in Previously Untreated Patients with Severe Hemophilia A Treated with Plasma-Derived or Recombinant Factor VIII: No Proof of Difference or Proof of No Difference? [O] . Andrea Messori, Valeria Fadda, Dario Maratea, 2014

机译：抑制剂发育中以前未经处理的血浆血糖A或重组因子viii治疗的患者的抑制率：没有差异的证据或无差别证明？
8. Cooperative Study of Spontaneously-Occurring Factor VIII Inhibitors in Patients with Hemophilia A [R] . Shapiro, S. S. 1981

机译：血友病a患者自发性因子VIII抑制剂的合作研究

Factor VIII inhibitors development following introduction of B-domain-deleted recombinant factor VIII in four hemophilia A previously treated patients

著录项

引文网络

相似文献

相关主题

期刊订阅